SRZN stock forecast, quote, news & analysis
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues... Show more
Why Surrozen (SRZN) Stock Is Down -12% in the Last 30 Days
Key Takeaways
- Surrozen (SRZN) shares declined roughly 12% over the last 30 days, falling from about $29.54 to near $25.94 amid post-rally consolidation and profit-taking.
- The pullback followed a sharp late-September surge driven by positive late-stage data from a competing Wnt-modulating drug candidate and progress on Surrozen's lead program.
- Over the last quarter, the stock still advanced roughly 31%, reflecting a substantially higher base from its pre-surge levels.
- Key catalysts include FDA clearance of the Investigational New Drug (IND) application for SZN-8141 and a $95.1 million private placement tranche that extended the company's cash runway into 2029.
- Investor attention is now focused on the start of the DUET Phase 1b/2a study and initial clinical data expected in 2027.
- For additional details, explore Surrozen's Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading strategies by exploring Trending AI Robots.
Surrozen (SRZN) Company Overview and Market Position
Surrozen, Inc. is a clinical-stage biotechnology company pioneering a new class of Wnt-based therapeutics designed to repair and restore tissue function, with a current focus on ophthalmology. The company develops tissue-specific, multifunctional antibodies that selectively modulate the Wnt signaling pathway, a key mediator of tissue repair, to address serious eye diseases with high unmet medical need.
Its lead candidate, SZN-8141, combines Frizzled 4 (Fzd4) agonism with vascular endothelial growth factor (VEGF) antagonism and is being developed for diabetic macular edema (DME) and neovascular age-related macular degeneration (wet AMD). The pipeline also includes SZN-8143, which adds interleukin-6 (IL-6) antagonism for DME, wet AMD, and uveitic macular edema, and SZN-413, a bi-specific antibody partnered with Boehringer Ingelheim under an agreement featuring up to roughly $586.5 million in milestone payments. Investors follow the stock closely for its differentiated dual-mechanism approach and near-term clinical catalysts.
Surrozen (SRZN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SRZN shares have pulled back approximately 12%, moving from a closing level near $29.54 to roughly $25.94. This decline reflects a period of consolidation and profit-taking after a dramatic late-September rally rather than a deterioration in the company's fundamental outlook.
By contrast, the stock remains sharply higher over the last quarter, advancing roughly 31% from a late-July level near $19.73. The broader trend shows a pronounced spike in late September, when shares briefly traded above $33 on record volume, followed by a gradual giveback into the mid-$20s. The net result is a stock that has held most of its quarterly gains while digesting a rapid re-rating.
What Drove SRZN Stock Price in the Last 30 Days
The recent move was shaped by two competing forces. On the catalyst side, positive Phase 2b/3 data from Merck's remigromig, a Fzd4-mediated Wnt agonist in DME, validated the Wnt-modulation approach that underpins Surrozen's platform and helped fuel the stock's surge. This was reinforced by the U.S. Food and Drug Administration's clearance of the IND application for SZN-8141, announced in early October, which enabled the program to advance into clinical development.
On the other side, the shares gave back ground as investors absorbed the dilutive impact of financing activity. In October, Surrozen closed the second tranche of its March 2025 private placement for approximately $95.1 million, issuing roughly 5.7 million shares of common stock along with pre-funded warrants and additional warrants. The expanded share count and near-term supply, combined with profit-taking after the sharp run-up, pressured the stock from its late-September highs. H.C. Wainwright raised its price target on the shares to $54 from $44 while maintaining a Buy rating, underscoring continued analyst support despite the pullback.
What Drove SRZN Stock Performance Over the Last Quarter
The quarter's larger narrative was a meaningful re-rating of Surrozen driven by validation of its core thesis. The submission of the IND application for SZN-8141 in early September, followed by FDA clearance in early October, transitioned the company from a preclinical-stage story into a clinical-stage one with a lead asset approaching first-in-human dosing.
Equally important was external validation of the Wnt pathway in retinal vascular disease. Merck's remigromig achieving its primary endpoint in a late-stage DME trial supported the therapeutic rationale for Surrozen's Fzd4-targeting programs. Combined with the $95.1 million financing tranche—which management said extends the company's cash runway into 2029 and funds completion of the DUET study—these developments strengthened the balance sheet and de-risked near-term execution. The multi-month trend therefore reflects a structurally higher valuation supported by clinical progress, financing, and favorable industry data.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a much larger ecosystem of hundreds of bots that trade thousands of tickers. Rather than listing every available strategy, the section surfaces the top-performing and most relevant bots so users can quickly identify approaches that align with their goals. The featured bots vary considerably in strategy, timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon trend-following systems. Because each bot operates with its own methodology and risk profile, the page offers a practical starting point for traders evaluating systematic, data-driven strategies. For those interested in exploring AI-driven trading tools, Trending AI Robots provides a useful overview of currently featured bots.
SRZN Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term catalyst is the initiation of the DUET Phase 1b/2a study of SZN-8141 in DME, with the first patient dosing expected in the fourth quarter of 2026 and initial data anticipated in 2027. Investors will monitor enrollment progress, safety and tolerability signals, and early biological activity readouts.
Beyond the clinic, attention will focus on capital management following the recent financing, the advancement of SZN-8143 toward early clinical development, and continued progress on the Boehringer Ingelheim partnership for SZN-413. Competitive dynamics in the retinal disease space—including the commercialization trajectory of competing anti-VEGF and Wnt-based therapies—will also influence sentiment, as will broader biotech risk appetite and macroeconomic conditions affecting small-cap healthcare names. These factors will shape how the market interprets Surrozen's execution over the coming quarters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SRZN in upward trend: price rose above 50-day moving average on October 19, 2026
SRZN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 48 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on SRZN as a result. In 73 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for SRZN just turned positive on October 27, 2026. Looking at past instances where SRZN's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +5.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRZN advanced for three days, in 247 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 156 of 180 cases where SRZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.666) is normal, around the industry mean (3.498). P/E Ratio (-0.774) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.837) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SRZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology